# China NMPA Drug Inspection - Pfizer Pharmaceuticals Co., Ltd. - Azithromycin dry suspension

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/pfizer-pharmaceuticals-co-ltd/6211877d-3f9a-4777-8147-2d332b9eb807/
Source feed: China

> China NMPA drug inspection for Pfizer Pharmaceuticals Co., Ltd. published June 17, 2021. Drug: Azithromycin dry suspension. 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Guangdong Provincial Drug Administration's Announcement Regarding Drug Sampling and Inspection Information (Issue 5, 2021)
- Company Name: Pfizer Pharmaceuticals Co., Ltd.
- Publication Date: 2021-06-17
- Drug Name: Azithromycin dry suspension
- Inspection Finding: Compliant with drug standards

Company: https://www.globalkeysolutions.net/companies/pfizer-pharmaceuticals-co-ltd/8b1407a5-b939-468d-a383-a7c7069b2207/